Skip to main
CLGN

CLGN Stock Forecast & Price Target

CLGN Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CollPlant Biotechnologies Ltd demonstrates a positive outlook driven by expanded supply agreements and leadership appointments aimed at enhancing North American growth, particularly through its proprietary rhCollagen products. The company's innovative Collink.3D technology is poised to differentiate it within the competitive landscape, especially in the fields of regenerative medicine and aesthetic applications, potentially unlocking significant market opportunities. Moreover, the establishment of a U.S.-based logistics center is expected to bolster sales of BioInk and rhCollagen, alongside new distribution agreements in Europe that will further strengthen the company's market presence and financial performance.

Bears say

CollPlant Biotechnologies Ltd faces a challenging financial outlook due to stagnant revenue growth across its key markets, particularly in the United States, where the company relies heavily on its regenerative and aesthetic medicine products. Additionally, the sales performance of the BioInk product and rhCollagen for medical aesthetics has not met expectations, indicating potential difficulties in market penetration and competitiveness. The company's reliance on income from business collaborators further exposes it to risks associated with partnership performance and market fluctuations, limiting its financial stability and growth potential.

CLGN has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CollPlant Biotechnologies Ltd - ADR (CLGN) Forecast

Analysts have given CLGN a Strong Buy based on their latest research and market trends.

According to 2 analysts, CLGN has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CollPlant Biotechnologies Ltd - ADR (CLGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.